News

Medscape13d
ACG Updates Guidance on Crohn’s Disease Management
Updated guidance from the ACG on the management of Crohn’s disease reflects the surge in development of therapeutic options ...
Healio4d
Latest from FDA: Zoryve foam, more psoriasis biosimilars, Keytruda for skin cancer
Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...
PharmiWeb10d
Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
EQS-News: Formycon AG / Key word (s): MiscellaneousTeva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany 26 ...
The Malaysian Reserve15d
Bio-Thera Solutions Receives Positive CHMP Opinion for USYMRO®(ustekinumab), a Biosimilar Referencing Stelara®
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing USYMRO® to the reference product ...
KELOLAND News20d
Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients - KELOLAND.com
INCHEON, South Korea, June 15, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA ® (ustekinumab ...
Biosimilars Market Worth US$72.29 Billion By 2035 With 7.5% CAGR Marketsandmarketstm
We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized ...
The Lancet4d
Progress in validation of treatment-response biomarkers in Crohn's disease?
Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...